Urinary CA125 peptides as biomarkers of ovarian cancer
US8642347B2 · kind B2 · utility
1Cited by
11References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 30, 2009 |
| Grant date | Feb 4, 2014 |
| Priority date | — |
| Expiry date | Jan 6, 2030 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K14/4748
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The present invention is directed to diagnostic methods based upon the detection of peptides derived from the degradation of CA125. In particular, it is concerned with assays of urine samples collected from women for the purpose of determining whether they are at increased risk for having ovarian cancer, have decreased their risk as the result of clinical or non-clinical procedures, to monitor the efficacy of a treatment method, or to determine whether cancer has recurred or advanced.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.